Academic Journal
ELISA F29 -A therapeutic efficacy biomarker in Chagas disease: Evaluation in pediatric patients treated with nifurtimox and followed for 4 years post-treatment.
| العنوان: | ELISA F29 -A therapeutic efficacy biomarker in Chagas disease: Evaluation in pediatric patients treated with nifurtimox and followed for 4 years post-treatment. |
|---|---|
| المؤلفون: | Rocio Rivero, Mónica Inés Esteva, Erya Huang, Leylen Colmegna, Jaime Altcheh, Ulrike Grossmann, Andrés Mariano Ruiz, CHICO and CHICO SECURE Study Groups |
| المصدر: | PLoS Neglected Tropical Diseases, Vol 17, Iss 6, p e0011440 (2023) |
| بيانات النشر: | Public Library of Science (PLoS) |
| سنة النشر: | 2023 |
| المجموعة: | Directory of Open Access Journals: DOAJ Articles |
| مصطلحات موضوعية: | Arctic medicine. Tropical medicine, RC955-962, Public aspects of medicine, RA1-1270 |
| الوصف: | Background Measurement of the success of antitrypanosomal treatment for Chagas disease is difficult, particularly in the chronic phase of the disease, because anti-Trypanosoma cruzi antibodies persist in serum for prolonged periods. We studied the effects of nifurtimox administered by two different treatment regimens on the T. cruzi calcium-binding flagellar protein F29 in children diagnosed with Chagas disease measured using an enzyme-linked immunosorbent assay (ELISA) technique (ELISA F29). Methods and principal findings In a phase 3, randomized, double-blind, parallel-group, historically controlled study (ClinicalTrials.gov NCT02625974), blood samples obtained from children diagnosed with Chagas disease and treated with nifurtimox for either 60 days or 30 days were analyzed using an ELISA with an F29 recombinant protein as the antigen, as well as conventional serological tests (recombinant ELISA and indirect hemagglutination assay). In an exploratory approach, serological response to nifurtimox treatment was evaluated for 4 years post-treatment. In both treatment groups, the number of patients with negative ELISA F29 values increased over the period of observation. The incidence rate of negative seroconversion using ELISA F29 was 22.94% (95% CI: 19.65%, 26.63%) in the 60-day treatment group and 21.64% (95% CI: 17.21%, 26.86%) in the 30-day treatment group. In the subpopulation of patients who tested seropositive for F29 before nifurtimox treatment, 88 patients (67.7%) in the 60-day regimen and 39 patients (59.1%) in the 30-day regimen were F29 seronegative at 4 years post-treatment. All patients who had a positive ELISA F29 test at baseline and seroconverted to negative measured by conventional serology reached seronegativity in ELISA F29 earlier than in conventional serology. Conclusions The results demonstrate a serological response to treatment with nifurtimox measured by the ELISA F29 test in children diagnosed with Chagas disease. The F29-based ELISA can be considered a potential early marker of response ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 1935-2727 1935-2735 |
| Relation: | https://doi.org/10.1371/journal.pntd.0011440; https://doaj.org/toc/1935-2727; https://doaj.org/toc/1935-2735; https://doaj.org/article/9a0ee13271994761b4d8354ed12dad65 |
| DOI: | 10.1371/journal.pntd.0011440 |
| الاتاحة: | https://doi.org/10.1371/journal.pntd.0011440 https://doaj.org/article/9a0ee13271994761b4d8354ed12dad65 |
| رقم الانضمام: | edsbas.E02DDB2 |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 19352727 19352735 |
|---|---|
| DOI: | 10.1371/journal.pntd.0011440 |